S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
OTCMKTS:SPHDF

Santhera Pharmaceuticals (SPHDF) Stock Forecast, Price & News

$10.29
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$10.29
▼
$10.29
50-Day Range
$0.68
▼
$10.29
52-Week Range
$0.68
▼
$1.20
Volume
N/A
Average Volume
3,788 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesShort Interest

SPHDF stock logo

About Santhera Pharmaceuticals (OTCMKTS:SPHDF) Stock

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

SPHDF Price History

SPHDF Stock News Headlines

September 8, 2023 | seekingalpha.com
Santhera Pharmaceuticals reports 1H results
September 8, 2023 | finance.yahoo.com
Santhera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Corner
September 24, 2023 | Behind the Markets (Ad)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
September 7, 2023 | finance.yahoo.com
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
July 31, 2023 | benzinga.com
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
July 31, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)
June 29, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Split
June 29, 2023 | finance.yahoo.com
Santhera Publishes Timeline of the Reverse Share Split
September 24, 2023 | Behind the Markets (Ad)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
June 27, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meeting
June 27, 2023 | finance.yahoo.com
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
June 21, 2023 | msn.com
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
June 20, 2023 | finance.yahoo.com
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023 | markets.businessinsider.com
Santhera Grants North America License For Vamorolone To Catalyst Pharma
June 20, 2023 | finance.yahoo.com
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
June 6, 2023 | finance.yahoo.com
Santhera Publishes Agenda for its Annual General Meeting
June 2, 2023 | seekingalpha.com
Santhera Pharmaceuticals GAAP EPS of -CHF1.17
June 1, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022
May 31, 2023 | finance.yahoo.com
Santhera Publishes Annual Report 2022
May 24, 2023 | thestreet.com
Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
May 13, 2023 | thestreet.com
Santhera Drug Wins European Approval for Rare Blindness Disease
April 27, 2023 | finance.yahoo.com
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
April 25, 2023 | finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed
April 25, 2023 | finance.yahoo.com
Vamorolone NDA mid-cycle review meeting by FDA completed
April 1, 2023 | finance.yahoo.com
Santhera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near Future
March 30, 2023 | barrons.com
Santhera Pharmaceuticals Holding AG
March 2, 2023 | finance.yahoo.com
Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
See More Headlines
Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SPHDF
CUSIP
N/A
CIK
N/A
Web
www.santhera.com
Phone
(161) 906-8950
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Thomas Meier Ph.D. (Age 61)
    Founder & Chairman
    Comp: $93.8k
  • Mr. Dario Eklund (Age 55)
    Chief Exec. Officer
    Comp: $912.62k
  • Mr. Andrew P. Smith CGMA (Age 60)
    FCMA, Chief Financial Officer
  • Mr. Oliver Strub (Age 60)
    Exec. VP, Gen. Counsel & Sec.
  • Mr. Günther Metz Ph.D. (Age 65)
    Head of Bus. Devel. & Exec. VP
  • Mr. Shabir Hasham M.D.
    Chief Medical Officer
  • Ms. Stephanie Brown B.Sc. (Age 62)
    M.B.A., Pres of North America
  • Mr. Marc Schrader
    Head of Technical Devel. & Operations
  • Ms. Eva Kalias
    Head of Investor Relations & Communications
  • Mr. Neville Kodkani M.D.
    Head of Global Marketing & Partner Management

Key Competitors

View All Competitors













SPHDF Stock - Frequently Asked Questions

How have SPHDF shares performed in 2023?

Santhera Pharmaceuticals' stock was trading at $14.10 at the beginning of the year. Since then, SPHDF stock has decreased by 27.0% and is now trading at $10.2920.
View the best growth stocks for 2023 here.

Are investors shorting Santhera Pharmaceuticals?

Santhera Pharmaceuticals saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 82,800 shares, a decrease of 27.6% from the August 15th total of 114,300 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 828.0 days.
View Santhera Pharmaceuticals' Short Interest.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Santhera Pharmaceuticals' stock symbol?

Santhera Pharmaceuticals trades on the OTCMKTS under the ticker symbol "SPHDF."

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Santhera Pharmaceuticals' stock price today?

One share of SPHDF stock can currently be purchased for approximately $10.29.

How can I contact Santhera Pharmaceuticals?

Santhera Pharmaceuticals' mailing address is Hohenrainstrasse 24, Pratteln, Basel-Landschaft (Basle. The official website for the company is www.santhera.com. The company can be reached via phone at (161) 906-8950.

This page (OTCMKTS:SPHDF) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -